Special Press
The End of the $5,000 Alzheimer’s Diagnostic Barrier
The FDA has officially cleared a breakthrough Alzheimer's blood test co-developed by Roche and Eli Lilly. This single-biomarker test, known as Elecsys pTau217, is set to dismantle the massive, multi-billion-dollar barriers of traditional diagnostics—such as $5,000 PET scans and invasive spinal taps.